BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34117807)

  • 1. Clinical features, diagnosis, and survival analysis of dogs with glioma.
    José-López R; Gutierrez-Quintana R; de la Fuente C; Manzanilla EG; Suñol A; Pi Castro D; Añor S; Sánchez-Masian D; Fernández-Flores F; Ricci E; Marioni-Henry K; Mascort J; Matiasek LA; Matiasek K; Brennan PM; Pumarola M
    J Vet Intern Med; 2021 Jul; 35(4):1902-1917. PubMed ID: 34117807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T2-FLAIR mismatch sign as an imaging biomarker for oligodendrogliomas in dogs.
    Garcia-Mora J; Parker RL; Cecere T; Robertson JL; Rossmeisl JH
    J Vet Intern Med; 2023; 37(4):1447-1454. PubMed ID: 37246729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canine intracranial gliomas: relationship between magnetic resonance imaging criteria and tumor type and grade.
    Bentley RT; Ober CP; Anderson KL; Feeney DA; Naughton JF; Ohlfest JR; O'Sullivan MG; Miller MA; Constable PD; Pluhar GE
    Vet J; 2013 Nov; 198(2):463-71. PubMed ID: 24051197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning predicts histologic type and grade of canine gliomas based on MRI texture analysis.
    Barge P; Oevermann A; Maiolini A; Durand A
    Vet Radiol Ultrasound; 2023 Jul; 64(4):724-732. PubMed ID: 37133981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging features of intracranial astrocytomas and oligodendrogliomas in dogs.
    Young BD; Levine JM; Porter BF; Chen-Allen AV; Rossmeisl JH; Platt SR; Kent M; Fosgate GT; Schatzberg SJ
    Vet Radiol Ultrasound; 2011; 52(2):132-41. PubMed ID: 21388463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of magnetic resonance imaging-based preoperative tumor volume with postsurgical survival time in dogs with primary intracranial glioma.
    MacLellan JD; Arnold SA; Dave AC; Hunt MA; Pluhar GE
    J Am Vet Med Assoc; 2018 Jan; 252(1):98-102. PubMed ID: 29244602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-pathologist agreement on diagnosis, classification and grading of canine glioma.
    Krane GA; Shockley KR; Malarkey DE; Miller AD; Miller CR; Tokarz DA; Jensen HL; Janardhan KS; Breen M; Mariani CL
    Vet Comp Oncol; 2022 Dec; 20(4):881-889. PubMed ID: 35856268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic histopathologic features of canine glial tumors.
    Merickel JL; Pluhar GE; Rendahl A; O'Sullivan MG
    Vet Pathol; 2021 Sep; 58(5):945-951. PubMed ID: 34219560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma with cribriform plate involvement in 6 dogs.
    Reyes VAA; Howerth EW; Blas-Machado U; Platt SR; Pavarini SP; Castro LT; Church ME; Rissi DR
    J Vet Diagn Invest; 2023 Nov; 35(6):800-805. PubMed ID: 37608783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally Occurring Canine Glioma as a Model for Novel Therapeutics.
    Hubbard ME; Arnold S; Bin Zahid A; McPheeters M; Gerard O'Sullivan M; Tabaran AF; Hunt MA; Pluhar GE
    Cancer Invest; 2018; 36(8):415-423. PubMed ID: 30234401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of oligodendroglioma in dogs based on magnetic resonance imaging.
    Amphimaque B; Durand A; Oevermann A; Vidondo B; Schweizer D
    J Vet Intern Med; 2022 Nov; 36(6):2104-2112. PubMed ID: 36366870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between histological tumor margins and magnetic resonance imaging signal intensities in brain neoplasia of dogs.
    Johnson PJ; Rivard BC; Wood JH; DiRubio ML; Henry JG; Miller AD
    J Vet Intern Med; 2022 May; 36(3):1039-1048. PubMed ID: 35488504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computed tomographic characteristics of primary brain tumors in 50 dogs.
    Turrel JM; Fike JR; LeCouteur RA; Higgins RJ
    J Am Vet Med Assoc; 1986 Apr; 188(8):851-6. PubMed ID: 3710874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].
    Daumas-Duport C; Koziak M; Miquel C; Nataf F; Jouvet A; Varlet P
    Neurochirurgie; 2005 Sep; 51(3-4 Pt 2):247-53. PubMed ID: 16292168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definitive-intent uniform megavoltage fractioned radiotherapy protocol for presumed canine intracranial gliomas: retrospective analysis of survival and prognostic factors in 38 cases (2013-2019).
    Debreuque M; De Fornel P; David I; Delisle F; Ducerveau MN; Devauchelle P; Thibaud JL
    BMC Vet Res; 2020 Oct; 16(1):412. PubMed ID: 33129320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical study of neural stem cell lineage markers in canine brains, gliomas, and a glioma cell line.
    Yoshida K; Chambers JK; Uchida K
    Vet Pathol; 2023 Jan; 60(1):35-46. PubMed ID: 36384382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of linear and volumetric criteria for the determination of therapeutic response in dogs with intracranial gliomas.
    Garcia Mora JK; Robertson J; Hsu FC; Shinn RL; Larson MM; Rylander CG; Whitlow CT; Debinski W; Davalos RV; B Daniel G; Rossmeisl JH
    J Vet Intern Med; 2022 May; 36(3):1066-1074. PubMed ID: 35274379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A methodological approach for deep learning to distinguish between meningiomas and gliomas on canine MR-images.
    Banzato T; Bernardini M; Cherubini GB; Zotti A
    BMC Vet Res; 2018 Oct; 14(1):317. PubMed ID: 30348148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canine spinal cord glioma.
    Rissi DR; Barber R; Burnum A; Miller AD
    J Vet Diagn Invest; 2017 Jan; 29(1):126-132. PubMed ID: 28074710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective review of 50 canine intracranial tumors evaluated by magnetic resonance imaging.
    Kraft SL; Gavin PR; DeHaan C; Moore M; Wendling LR; Leathers CW
    J Vet Intern Med; 1997; 11(4):218-25. PubMed ID: 9298476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.